MX2022001944A - Un metodo para diagnosticar o monitorear la funcion renal o diagnosticar la disfuncion renal en pacientes pediatricos. - Google Patents

Un metodo para diagnosticar o monitorear la funcion renal o diagnosticar la disfuncion renal en pacientes pediatricos.

Info

Publication number
MX2022001944A
MX2022001944A MX2022001944A MX2022001944A MX2022001944A MX 2022001944 A MX2022001944 A MX 2022001944A MX 2022001944 A MX2022001944 A MX 2022001944A MX 2022001944 A MX2022001944 A MX 2022001944A MX 2022001944 A MX2022001944 A MX 2022001944A
Authority
MX
Mexico
Prior art keywords
kidney
subject
therapy
monitoring
level
Prior art date
Application number
MX2022001944A
Other languages
English (en)
Inventor
Andreas Bergmann
Wildt Saskia De
Original Assignee
Sphingotec Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sphingotec Gmbh filed Critical Sphingotec Gmbh
Publication of MX2022001944A publication Critical patent/MX2022001944A/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/34—Genitourinary disorders
    • G01N2800/347—Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy

Abstract

La materia objeto de la presente invención es un método para (a) diagnosticar o monitorear la función renal en un sujeto o (b) diagnosticar disfunción renal en un sujeto o (c) predecir o monitorear el riesgo de un evento adverso en un sujeto enfermo, en donde dicho evento adverso se selecciona del grupo que comprende el empeoramiento de la función renal, incluida la insuficiencia renal, la pérdida de la función renal y la enfermedad renal en fase terminal o la muerte debido a una disfunción renal, incluida la insuficiencia renal, la pérdida de la función renal y la enfermedad renal en fase terminal o (d) predecir o monitorear el éxito de una terapia o intervención que comprende: • determinar el nivel de Pro-Encefalina o fragmentos de la misma de al menos 5 aminoácidos en un fluido corporal obtenido de dicho sujeto; y a) correlacionar dicho nivel de Pro-Encefalina o fragmentos de la misma con la función renal en un sujeto o b) correlacionar dicho nivel de Pro-Encefalina o fragmentos de la misma con disfunción renal, en donde un nivel elevado por encima de un cierto umbral es predictivo o diagnóstico para disfunción renal en dicho sujeto o c) correlacionar dicho nivel de Pro-Encefalina o fragmentos de la misma con dicho riesgo de un evento adverso en un sujeto enfermo, en donde un nivel elevado por encima de un cierto umbral es predictivo de un mayor riesgo de dichos eventos adversos o d) correlacionar dicho nivel de Pro-Encefalina o fragmentos de la misma con el éxito de una terapia o intervención en un sujeto enfermo, en donde un nivel por debajo de cierto umbral es predictivo para el éxito de la terapia o intervención, en donde dicha terapia o intervención puede ser terapia de reemplazo renal o puede ser el tratamiento con ácido hialurónico en pacientes que han recibido reemplazo renal o predecir o monitorear el éxito de la terapia o intervención puede ser la predicción o el monitoreo de la recuperación de la función renal en pacientes con insuficiencia renal antes y después de la terapia de reemplazo renal y/o intervenciones farmacéuticas.
MX2022001944A 2019-08-15 2020-08-14 Un metodo para diagnosticar o monitorear la funcion renal o diagnosticar la disfuncion renal en pacientes pediatricos. MX2022001944A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19191968 2019-08-15
PCT/EP2020/072916 WO2021028582A1 (en) 2019-08-15 2020-08-14 A method for diagnosing or monitoring kidney function or diagnosing kidney dysfunction in pediatric patients

Publications (1)

Publication Number Publication Date
MX2022001944A true MX2022001944A (es) 2022-03-11

Family

ID=67659003

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022001944A MX2022001944A (es) 2019-08-15 2020-08-14 Un metodo para diagnosticar o monitorear la funcion renal o diagnosticar la disfuncion renal en pacientes pediatricos.

Country Status (9)

Country Link
US (1) US20220291234A1 (es)
EP (1) EP4014049A1 (es)
JP (1) JP2022544942A (es)
CN (1) CN114364984A (es)
AU (1) AU2020328194A1 (es)
BR (1) BR112022001417A2 (es)
CA (1) CA3146885A1 (es)
MX (1) MX2022001944A (es)
WO (1) WO2021028582A1 (es)

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU634716B2 (en) 1988-08-01 1993-03-04 Ciba Corning Diagnostics Corp. Method for detection of an analyte using acridinium esters and liposomes
US6818418B1 (en) 1998-12-10 2004-11-16 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
EP1427750B1 (en) 2001-08-30 2010-12-08 Biorexis Pharmaceutical Corporation Modified transferrin fusion proteins
WO2003103475A2 (en) 2002-06-07 2003-12-18 Dyax Corp. Prevention and reduction of blood loss
US20050164301A1 (en) 2003-10-24 2005-07-28 Avidia Research Institute LDL receptor class A and EGF domain monomers and multimers
US20100028995A1 (en) 2004-02-23 2010-02-04 Anaphore, Inc. Tetranectin Trimerizing Polypeptides
WO2006032436A2 (en) 2004-09-21 2006-03-30 Nascacell Technologies Ag. Use of microproteins as tryptase inhibitors
ES2373832T3 (es) 2007-12-19 2012-02-09 Affibody Ab Polipéptido derivado de proteína a y capaz de unirse a pdgf.
DK2358746T3 (da) 2008-11-03 2020-12-21 Molecular Partners Ag Bindingsproteiner til inhibering af vegf-a-receptorinteraktionen
AU2010288542B2 (en) 2009-08-27 2014-05-22 Covagen Ag IL-17 binding compounds and medical uses thereof
KR101353677B1 (ko) 2009-12-14 2014-02-12 쉴 프로테인즈 게엠베하 피브로넥틴의 엑스트라도메인 ｂ에 대한 특이적 결합 활성을 갖는 변형된 유비퀴틴 단백질
WO2011154420A2 (en) 2010-06-08 2011-12-15 Pieris Ag Tear lipocalin muteins binding il-4 r alpha
ES2674822T3 (es) * 2012-10-02 2018-07-04 Sphingotec Gmbh Método para diagnosticar o monitorizar la función renal o diagnosticar la disfunción renal

Also Published As

Publication number Publication date
JP2022544942A (ja) 2022-10-24
BR112022001417A2 (pt) 2022-05-24
US20220291234A1 (en) 2022-09-15
AU2020328194A1 (en) 2022-03-17
CN114364984A (zh) 2022-04-15
WO2021028582A1 (en) 2021-02-18
CA3146885A1 (en) 2021-02-18
EP4014049A1 (en) 2022-06-22

Similar Documents

Publication Publication Date Title
ATE456055T1 (de) Diagnoseverfahren für erkrankungen im zusammenhang mit hirnschäden
WO2008118148A3 (en) Adiponectin for the treatment and diagnosis of albuminuria
MX2022001944A (es) Un metodo para diagnosticar o monitorear la funcion renal o diagnosticar la disfuncion renal en pacientes pediatricos.
Pothen et al. Drug usage pattern in chronic kidney disease patients undergoing maintenance hemodialysis
Bolignano et al. Pulmonary hypertension: a neglected risk condition in renal patients?
Gao et al. Etiological factors, prognostic assessment, and outcomes of patients with acute kidney injury and multiple organ dysfunction syndrome
US20160310713A1 (en) Method and Use of Draining Fluid above the Cribriform Plate
JP2022512284A (ja) 血液透析を用いた家庭用ペットにおける腎不全の治療
Whitcomb Gene mutations as a cause of chronic pancreatitis
Khasawnah et al. Hematological and biochemical findings among Jordanian patient with end stage renal disease
Lakman et al. The evaluation of effect of various outcomes of kidney transplantation surgery on economic costs under treatment of kidneys chronic disease
Royakkers et al. Can serum and urine levels of cystatin C predict renal recovery in patients treated with renal replacement therapy in the ICU?
Rocca-Nación et al. Cardiovascular risk, fatty liver disease, glucose and insulin curve among prediabetes phenotypes in Peruvian population
Kotb et al. MO625 INHIBITION OF SGLT-2 CANNOT RESCUE NEPHRIN EXPRESSION IN DIABETIC NEPHROPATHY
Shwaib et al. PS 08-49 AGE SPECIFIC PREVALENCE OF HYPERTENSION, SOCIO-DEMOGRAPHIC AND BEHAVIORAL CHARACTERISTICS OF END STAGE RENAL DISEASE PATIENTS ON REGULAR HAEMODIAYSIS IN A DEVELOPING A COUNTRY.
Nakaya et al. Transplant-Ineligible Symptomatic but Indolent Multiple Myeloma Shows Better Prognosis with Conventional Agents
Giurguis Comparison of characteristics of centers practicing incremental vs. conventional approaches to hemodialysis delivery–postdialysis recovery time and patient survival
Ching et al. PS 08-50 BLOOD PRESSURE LEVELS AND DECLINE IN RENAL FUNCTION AMONG PATIENTS WITH TREATED HYPERTENSION: A 15-YEAR RETROSPECTIVE STUDY.
Bezrodna et al. PS-C33-11: FACTORS RELATED TO DETERIORATED KIDNEY FUNCTION IN RESISTANT HYPERTENSION PATIENTS
Piezzi Hypomagnesaemia: case report
Ekart et al. PP. 11.03: EFFECT OF DIFFERENT DIALYSATE SODIUM CONCENTRATION ON BLOOD PRESSURE IN HEMODIALYSIS PATIENTS: A RANDOMIZED STUDY
Ali SPECTRUM OF RENAL DISEASES AMONG PATIENTS PRESENTING FOR ACUTE HEMODIALYSIS IN FAYOUM UNIVERSITY HOSPITAL
Gunathilake Atorvastatin/pregabalin
Tappa The Impacts of SARS-CoV-2 on Chronic Kidney Disease
Krüger et al. SP327 Inhibition of p53 improves renal outcome in adenine crystal-induced nephropathy